{"analyses":[{"ciLowerLimit":"0.653","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.683","estimateComment":"Odds ratio and 95% CIs were estimated by a stratified analysis using the Cochran-Mantel-Haenszel method.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Odds Ratio (OR)","paramValue":"1.049"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"74.8","upperLimit":"85.5","value":"80.5"},{"groupId":"OG001","lowerLimit":"75.9","upperLimit":"86.4","value":"81.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"228"}],"units":"Participants"}],"description":"Patient-reported convenience was measured by the Patient-reported Convenience with Carfilzomib-dosing Schedule Question. The items in the questionnaire were categorized as 'Convenient', which included responses of 'Very Convenient' and 'Convenient', and 'Inconvenient' which included responses of 'Inconvenient' and 'Very Inconvenient'. The 95% CIs were estimated using the Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib was administered twice-weekly intravenously as a 10 ± 5 minute infusion using an infusion pump on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The dose was 20 mg/m\\^2 on Days 1 and 2 of Cycle 1 and 27 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG000","title":"Twice-weekly KRd 20/27 mg/m^2"},{"description":"Carfilzomib was administered once-weekly intravenously as a 30 ± 5 minute infusion using an infusion pump on Days 1, 8, and 15 of each 28-day cycle. The dose was 20 mg/m\\^2 on Day 1 of Cycle 1 and 56 mg/m\\^2 beginning on Day 8 of Cycle 1 and thereafter. Participants also received lenalidomide 25 mg daily orally on Days 1 to 21 of each cycle and dexamethasone 40 mg weekly orally or intravenously. Participants were treated for up to 12 28-day cycles.","id":"OG001","title":"Once-weekly KRd 20/56 mg/m^2"}],"paramType":"NUMBER","populationDescription":"The ITT population included all randomized participants.","reportingStatus":"POSTED","timeFrame":"Day 28 of Cycle 4","title":"Percentage of Participants Who Reported Convenience as Measured by the Patient-reported Convenience With Carfilzomib-dosing Schedule Question","type":"SECONDARY","unitOfMeasure":"percentage of participants"}